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Just over three decades ago, a new outbreak of opportunistic in-fections and Kaposi’s sarcoma was reported in a small number of homosexual men in California and New York.1,2 This universally fatal disease, which was 
eventually called the acquired immunodeficiency syndrome (AIDS), was associated 
with a complete loss of CD4+ T cells. Within the first year of its description, the 
disease was also identified in patients with hemophilia, users of injection drugs, 
blood-transfusion recipients, and infants born to affected mothers. Soon thereaf-
ter, a heterosexual epidemic of AIDS was reported in Central Africa, preferentially 
affecting women.3,4 Little did we know at the time that this small number of cases 
would eventually mushroom into tens of millions of cases, becoming one of the 
greatest pandemics of modern times.
Within 2 years after the initial reports of AIDS, a retrovirus, later called the 
human immunodeficiency virus (HIV), was identified as the cause of AIDS.5 Diag-
nostic tests were developed to protect the blood supply and to identify those in-
fected. Additional prevention measures were implemented, including risk-reduc-
tion programs, counseling and testing, condom distribution, and needle-exchange 
programs. However, HIV continued to spread, infecting 10 million persons within 
the first decade after its identification.
The second decade of AIDS was marked by further intensification of the epi-
demic in other areas of the world, including the southern cone of Africa, which 
saw an explosive HIV epidemic. Asia and the countries of the former Soviet Union 
also reported a marked increase in the spread of HIV. However, by the mid-1990s, 
with the discovery of highly active antiretroviral therapy, rates of death in devel-
oped countries started to decline. The use of antiretroviral drugs during preg-
nancy also resulted in a substantial decline in mother-to-child transmission of HIV 
in high-income countries. However, without access to antiretroviral drugs in low- 
and middle-income countries, rates of death and mother-to-child transmission 
continued to increase, with 2.4 million deaths and more than 3 million new infec-
tions reported in 2001. Of these new infections, two thirds occurred in sub-Saharan 
Africa.6
In ter nationa l R esponse t o A IDS — a Gl ob a l He a lth 
Model
It was not until the third decade of the epidemic that the world’s public health of-
ficials, community leaders, and politicians united to combat AIDS. In 2001, the 
United Nations General Assembly endorsed a historic Declaration of Commitment 
on HIV/AIDS, a commitment that was renewed in 2011.7 These actions resulted in 
the formation of the Global Fund to Fight AIDS, Tuberculosis, and Malaria, which 
was established to finance anti-AIDS activities in developing countries. In 2003, 
President George W. Bush announced the President’s Emergency Plan for AIDS 
An interactive 
graphic including 
a prevalence map, 
a timeline, and 
details of HIV 
structure and life 
cycle is available 
at NEJM.org 
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on June 11, 2013. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
Global Health
n engl j med 368;23 nejm.org june 6, 2013 2211
Relief (PEPFAR), which allocated billions of dol-
lars to the countries hardest hit by AIDS.
This unprecedented global response to the 
AIDS pandemic can serve as a model for the re-
sponse to other global health threats. For ex-
ample, the global AIDS response incorporated a 
multisectoral approach that involved public health 
officials, clinicians, politicians, and leaders in 
civil society, business and labor, the armed forces, 
and the law, working in concert and with finan-
cial resources in excess of $15 billion per year8 to 
reduce the incidence of HIV infection and associ-
ated mortality. The response to the pandemic re-
quired a coordinated global effort, which has 
been led by the Joint United Nations Program on 
HIV/AIDS (UNAIDS) since 1996. This transforma-
tional response helped redefine what is meant by 
health diplomacy and led to a new culture of ac-
countability in international development. Tiered 
pricing of medicines became commonplace, and 
renewed optimism provided a boost for research 
on other neglected global health issues. This re-
sponse to the AIDS pandemic highlighted the 
shortage of health care workers, inadequate avail-
ability of essential medications, and weaknesses 
in primary health care and public health systems. 
The stigma of HIV infection and inequities in the 
care of those infected focused attention on social 
and medical equity and human rights.
Although it has been argued that the provi-
sion of health care for patients with other condi-
tions may have suffered from “vertical” AIDS 
programs (i.e., programs focused exclusively on 
AIDS), especially because of their recruitment of 
scarce health care workers,9 there is also evidence 
that the AIDS response has had multiple col-
lateral benefits, including a major increase in 
attention to and funding for global health issues, 
particularly malaria and tuberculosis, and a 
strengthening of services for maternal and child 
health in some countries.10-12 The unified and 
integrated response to AIDS, although far from 
perfect, can serve as a model for society’s future 
response to the growing epidemic of chronic 
diseases, obesity, and injuries, along with mater-
nal and child health.13
The Fourth Dec a de of A IDS
UNAIDS estimates that in 2011, a total of 34.2 
million persons were living with HIV infection, 
as compared with 29.1 million in 2001; 2.5 mil-
lion persons were newly infected in 2011, a 22% 
decline from the number in 2001, and 1.7 mil-
lion died, a decline of 26% from 2005, when the 
number of AIDS deaths peaked at 2.3 million.8,14 
Similarly, the number of new infections among 
neonates and infants decreased from a peak of 
570,000 in 2003 to 330,000 in 2011 as a result 
of interventions to prevent mother-to-child trans-
mission.
However, these global figures hide a wide di-
versity. Figure 1 shows the prevalence of HIV in-
fection among adults according to country, with 
sub-Saharan Africa continuing to be the most af-
fected continent, followed by Eastern Europe and 
the Caribbean.15 A special case is southern Africa, 
where HIV infection has become hyperendemic, 
with an overall prevalence among adults of up to 
31% in Swaziland, 25% in Botswana, and 17% in 
South Africa. In Swaziland, the prevalence among 
women between the ages of 30 and 34 years is an 
astonishing 54%.7 Even within a country, the 
prevalence of HIV infection varies widely accord-
ing to region and risk group. In 2010, the preva-
lence of antenatal HIV infection in South Africa 
ranged from 18.4% in the Northern Cape prov-
ince to 39.5% in KwaZulu Natal.16 Men who have 
sex with men, female sex workers, users of injec-
tion drugs, truck drivers, fishermen, and military 
personnel are disproportionately affected around 
the world.17-22
There is also heterogeneity in epidemiologic 
trends. Whereas the spread of HIV infection is 
slowing in most regions, the incidence of infec-
tion continues to increase in Eastern Europe and 
several Asian countries.14 There is also a resur-
gence of HIV infection caused by increased risk 
behavior among men who have sex with men in 
several European cities — for example, a reported 
68% increase in sexual risk behavior among such 
men in Amsterdam23 — in spite of high rates of 
HIV testing and access to antiretroviral therapy. 
At the same time, HIV infection is spreading to 
previously unaffected populations, such as injec-
tion-drug users in parts of Africa and men who 
have sex with men across Asia and Africa, where 
widespread homophobia drives these men under-
ground.
Pro gr ess in Tr e atmen t of HI V 
Infec tion
Twenty-six antiretroviral drugs have been li-
censed for the treatment of HIV infection. The 
availability of these drugs led to reductions in 
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mortality starting in the late 1990s in the United 
States and Europe. Subsequent reductions in the 
cost of antiretroviral therapy, the availability of 
generic antiretroviral drugs, and increases in in-
ternational financial aid led to a marked expan-
sion in drug availability. As a result, the number 
of persons receiving antiretroviral therapy in 
low- and middle-income countries rose from less 
than 200,000 persons in 2001 to 8 million per-
sons in 201114 (Fig. 2). In addition, the death 
rates in some of the hardest-hit countries have 
started to decline.24
With the life expectancy of a patient with HIV 
infection receiving treatment approaching that 
of a person without HIV infection,25,26 there has 
been an increased emphasis on starting antiret-
roviral therapy as early as possible in the course 
of infection. The revised 2012 guidelines of the 
U.S. Department of Health and Human Services 
recommend the initiation of antiretroviral ther-
apy in all persons with HIV infection.27 These 
recommendations are based on evidence regard-
ing the association between ongoing HIV repli-
cation and disease progression. In addition, be-
cause the use of antiretroviral therapy prevents 
the transmission of HIV in discordant couples 
(i.e., in which one person is infected and the 
other is not),28 the guidelines recommend that 
such therapy be offered to all patients with HIV 
infection in order to reduce the risk for their 
sexual partners.
At variance with the U.S. and European 
guidelines,29 World Health Organization guide-
lines continue to recommend the initiation of 
antiretroviral therapy in all persons with CD4 
counts of 350 per cubic millimeter or less, with 
recognition of the limitations of cost and avail-
ability in many countries.30 However, all guide-
lines strongly recommend antiretroviral therapy 
for all infected persons (regardless of the CD4 
count) who are pregnant or who have a history 
of an AIDS-defining illness, tuberculosis, or 
coinfection with hepatitis B virus. The guide-
lines were recently updated to recommend anti-
retroviral therapy for HIV-discordant couples31 
(Table 1).
Despite advances in the accessibility of anti-
retroviral therapy, many challenges remain in 
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Figure 1. World Map of Prevalence of HIV Infection.
Data are from UNAIDS,15 UNICEF (www.unicef.org), and the World Bank (www.worldbank.org). An interactive version of this map is 
available at NEJM.org.
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on June 11, 2013. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
Global Health
n engl j med 368;23 nejm.org june 6, 2013 2213
the provision of care for persons with HIV infec-
tion. In the United States, the Centers for Dis-
ease Control and Prevention estimates that 1.2 
million persons were living with HIV infection 
in 2008; of these persons, only 28% ultimately 
had suppressed viral levels, meaning that a ma-
jority were infectious owing to an insufficient 
uptake of testing, access to antiretroviral ther-
apy, and adherence to therapy.32-34 In one study in 
Mozambique involving 7005 persons with HIV 
infection, only half were enrolled in programs 
providing care, and only a small proportion ul-
timately started antiretroviral therapy and main-
tained adherence to the regimen at a rate of more 
than 90% for more than 180 days35 (Fig. 3). These 
numbers reflect insufficient access and adher-
ence to treatment that are mostly due to an in-
consistent pattern of diagnosis, linkage to care, 
use of the CD4 count as a threshold for the ini-
tiation of therapy, and retention in care. In sub-
Saharan Africa, the proportion of the population 
that is being tested for HIV remains low. In low- 
and middle-income countries, the average CD4 
count at the time of initiation of antiretroviral 
therapy remains low, with a median of 124 cells 
per cubic millimeter.36 Intensified efforts are 
needed to identify persons who are infected, 
initiate therapy with standardized effective regi-
mens, and encourage adherence to the regimen 
and retention in the program of care. Only with 
success at each stage in the continuum of care 
can the ultimate goals of improving health, ex-
tending lives, and preventing further HIV trans-
mission be achieved.
E volu tion of Pr e v en tion 
S tr ategies
A reduction in the incidence of HIV infection has 
been a top priority for AIDS control. The initial 
prevention strategy was based on behavioral 
change: abstinence, fidelity to a single partner, 
and use of a condom. This strategy met with only 
limited success, with Thailand’s 100% condom 
campaign and Uganda’s initial AIDS response 
being exceptions.37,38 There is growing evidence 
that the relative decline of more than 25% in the 
incidence of HIV infection from 2000 through 
2010 in several African countries is the result of 
behavioral change.39 The rate of condom use 
continues to increase, with several countries (in-
cluding South Africa, India, and Botswana) re-
porting a rate of condom use of more than 75% 
during high-risk sexual intercourse.6 However, 
condom use is still low in many other countries. 
A cause for concern is the finding that in several 
African countries (e.g., Uganda, Rwanda, and 
Zimbabwe), the number of men and women re-
porting multiple partners was higher in 2011 
than the number 5 to 10 years earlier.14
Among injection-drug users, access to sterile 
injection equipment and drug-substitution ther-
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Figure 2. Number of Persons Receiving Antiretroviral Therapy in Low- and Middle-Income Countries, According to 
Region (2002–2011).
Data are from UNAIDS.14
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Table 1. Guidelines for the Initiation of Antiretroviral Drugs in Adults with HIV Infection.*
Clinical Condition or CD4 Count Recommendations to Start Treatment
DHHS 201327 EACS 201229 WHO 201030,31†
CD4 count
≤350 cells/mm3 Yes (AI) Yes Yes
>350–500 cells/mm3 Yes (AII) Asymptomatic patients, consider 
therapy; symptomatic patients, 
yes
Stage 1 or 2, defer therapy; 
stage 3 or 4, yes
>500 cells/mm3 Yes (BIII) Asymptomatic patients, defer ther­
apy; symptomatic patients, yes
Stage 1 or 2, defer therapy; 
stage 3 or 4, yes
Pregnancy Yes (AI) Yes Yes
History of AIDS­defining illness Yes (AI) Yes Yes
HIV­associated nephropathy Yes (AII) Yes Yes
Coinfection with tuberculosis Yes (AII) Yes Yes
Coinfection with HBV Yes (AII) Yes, when treatment is indicated for 
HBV; defer therapy if HBV infec­
tion does not require treatment 
and CD4 count is >500 cells/
mm3; consider therapy if CD4 
count is 350–500 cells/mm3
Yes, when treatment is indicat­
ed for HBV infection
Coinfection with hepatitis C virus Yes (BII) Yes, if CD4 count is <500 cells/
mm3; defer or consider therapy if 
CD4 count is ≥500 cells/mm3
Not specified
Risk of transmission
Perinatal transmission Yes (AI) Yes Yes
Heterosexual transmission Yes (AI) Strongly consider Yes
Other sexual­transmission risk 
groups
Yes (AIII) Strongly consider Not specified
Preferred combination regimens
Patients receiving first­time 
therapy
Tenofovir and emtricitabine,‡ plus 
one of the following: efavirenz 
(AI), ritonavir­boosted atazana­
vir (AI), ritonavir­boosted dar u­
navir (AI), or raltegravir (AI)
Tenofovir and emtricitabine‡ or 
 abacavir and lamivudine, plus 
one of the following: nevira pine, 
efavirenz, rilpivirine; ritonavir­
boosted atazanavir, darunavir,  
or lopinavir; or raltegravir
Zidovudine or tenofovir, plus 
lamivudine or emtricitabine, 
plus efavirenz or nevirapine
Coinfection with tuberculosis§ Regimens listed above Tenofovir and emtricitabine,‡ plus 
either efavirenz or ritonavir­
boosted protease inhibitor, plus 
rifabutin
Zidovudine or tenofovir, plus 
lamivudine or emtricitabine, 
plus efavirenz
Coinfection with HBV Tenofovir and emtricitabine,‡ plus 
efavirenz (AI) or regimens 
 listed above
Tenofovir plus emtricitabine,‡ plus 
efavirenz or same regimens as 
those for all patients
Tenofovir and emtricitabine,‡ 
plus efavirenz
Pregnancy Zidovudine and lamivudine, plus 
ritonavir­boosted atazanavir or 
lopinavir (AI)
Zidovudine and lamivudine, plus 
ritonavir­boosted lopinavir, 
 saquinavir, or atazanavir
Zidovudine and lamivudine 
plus nevirapine
* Recommendations are rated as follows: A, strong; B, moderate; and C, optional. Evidence is rated as follows: I, data from randomized, con­
trolled trials; II, data from well­designed, nonrandomized trials or observational cohort studies with long­term clinical outcomes; and III, ex­
pert opinion. DHHS denotes Department of Health and Human Services, EACS European AIDS Clinical Society, HBV hepatitis B virus, and 
WHO World Health Organization.
† WHO stages include the following symptoms: stage 1, asymptomatic with generalized lymphadenopathy; stage 2, moderate weight loss, 
 recurrent respiratory and oral infections, and herpes zoster; stage 3, severe weight loss, chronic diarrhea, thrush, severe bacterial infections, 
and tuberculosis within the past 2 years; stage 4, opportunistic infections, HIV wasting syndrome, and HIV encephalopathy.
‡ Lamivudine can be used instead of emtricitabine and vice versa.
§ In patients with HIV infection and tuberculosis, antiretroviral therapy should be started within 2 weeks after the initiation of treatment for 
tuberculosis if the CD4 count is less than 50 cells per cubic millimeter (AI). For patients with a CD4 count of 50 cells or more per cubic 
 millimeter, therapy can be delayed beyond 2 weeks. The dose of antiretroviral therapy should be adjusted when used in combination with 
 rifampin or rifabutin.
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apy (referred to as harm reduction) is highly ef-
fective in reducing the spread of HIV infection.40 
Yet several countries in Eastern Europe and Asia 
in which HIV epidemics are driven by injection-
drug use continue to use ineffective, punitive 
approaches. The result is a sustained high inci-
dence of HIV infection, which also feeds the 
sexual spread of HIV.41 Structural approaches,42 
such as programs to reduce violence against 
women43 and the use of cash transfers (i.e., cash 
payments that can be used for food purchases, 
transportation, education, health care, or other 
expenses) among adolescent school girls in Ma-
lawi,44 should be integrated more widely into 
HIV-prevention agendas. In addition, laws that 
drive men with same-sex partners underground 
or prohibit harm reduction for injection-drug 
users can be major obstacles to effective HIV 
prevention.17 That such laws can be reversed was 
illustrated in India, where same-sex relations 
were decriminalized in 2009.
Biomedic a l A dva nces  
in Pr e v en tion
Male Circumcision
The first major biomedical breakthrough in pre-
vention was the finding of reduced susceptibility 
to HIV infection among circumcised men, with 
an efficacy rate of 50 to 60% shown in three clin-
ical trials.45-47 Three years after the completion 
of the circumcision trial in Rakai, Uganda, high 
rates of community effectiveness (73%) in de-
creasing the incidence of HIV infection have 
been reported.48 With an estimated cost per in-
fection averted in the range of $150 to $900 over a 
10-year period (depending on the local incidence 
of HIV infection), male circumcision appears to 
be one of the most cost-effective preventive ap-
proaches, requiring only a one-time intervention.49
Preexposure Prophylaxis
Preexposure prophylaxis (i.e., the use of antiret-
roviral therapy before sex) with 1% tenofovir gel 
was reported to reduce HIV acquisition by 39% in 
women.50 Daily use of oral combination prophy-
laxis with tenofovir and emtricitabine among HIV-
negative homosexual men who had multiple part-
ners reduced HIV acquisition by 44%.51 In both 
studies, greater efficacy was observed among 
persons who had high levels of adherence to the 
medication regimen. Daily use of tenofovir or 
tenofovir plus emtricitabine reduced HIV acquisi-
tion by 66% and 73%, respectively, among unaf-
fected partners in HIV-discordant couples52 and 
among young heterosexuals in Botswana.53 Al-
though these findings are encouraging, two 
studies had conflicting results, with findings of 
no efficacy for either oral or gel tenofovir.54,55 
Such discrepancies in results may be due to low 
adherence to the drug regimens or differences in 
mucosal penetration. Recently, the Food and 
Drug Administration approved the daily use of 
oral emtricitabine and tenofovir disoproxil fuma-
rate (Truvada, Gilead Sciences) for preexposure 
prophylaxis in combination with safer sex prac-
tices to reduce the risk of sexually acquired HIV 
infection among adults at high risk.
Treatment as Prevention
Viral load is the single greatest risk factor for all 
modes of HIV transmission,56 and treatment as 
prevention is based on the fact that antiretroviral 
therapy can reduce plasma and genital viral loads 
to undetectable levels, thereby reducing infec-
tiousness.28 This principle was first proved for 
the prevention of mother-to-child transmission57 
and was subsequently proved for the prevention 
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of sexual transmission among discordant cou-
ples, with a reduction of 96% in the transmission 
rate.28 This shift in focus from the use of antiret-
roviral agents for the treatment of HIV infection 
to their prophylactic use for the elimination of 
viral transmission has inspired optimism for 
achieving the goal of an AIDS-free generation.
Combination Prevention
There is consensus that no single intervention 
can stop the spread of HIV and that combination 
prevention is the best approach.58 Effective bio-
medical interventions coupled with behavioral 
and structural approaches may now successfully 
reduce the incidence of HIV infection to very low 
levels and ultimately control the epidemic. There 
is also a need to test in randomized trials the ef-
ficacy of treatment as prevention at the popula-
tion level and to determine the optimal program 
design (in combination with specific preventive 
interventions), as well as ensuring good treat-
ment coverage for persons in immediate need of 
clinical treatment.
From the perspectives of both efficacy and 
cost-effectiveness, HIV prevention should focus 
on populations at highest risk for transmission 
and should be customized to a wider range of 
realities than is currently the case. All compo-
nents of combination prevention require some 
form of behavioral intervention, including ad-
herence to condom use, antiretroviral-based 
prevention, and prevention of behaviors associ-
ated with an increased risk of infection. How-
ever, even when the most effective HIV interven-
tions are used, most mathematical models 
suggest that by 2031 — 50 years after the iden-
tification of AIDS — there may still be as many 
as 1 million new infections globally every 
year.59,60 Although a vaccination trial in Thai-
land showed an efficacy of 31%, providing a 
much-needed boost to vaccine research,61 the 
search for such effective prophylaxis still eludes 
investigators.
The Ch a llenges A he a d
After 30 years of the AIDS epidemic, more than 
34 million persons are still living with HIV infec-
tion worldwide, and the global response will 
clearly have to be sustained for at least several 
decades. An impressive array of evidence-based 
interventions can be implemented to treat estab-
lished infections and prevent new ones. Studies 
of high-risk populations have shown that HIV in-
fection can be prevented even in the most chal-
lenging settings. Nevertheless, UNAIDS reports 
that only 60% of sex workers, 46% of injection-
drug users, and 40% of men who have sex with 
men were reached by HIV-prevention programs 
in 2008, and the incidence of HIV infection 
is rising again in several countries, including 
Uganda.8,14
In 2011, less than 25% of all persons with 
HIV infection had access to antiretroviral thera-
py or had virologic suppression from receipt of 
such therapy.14 To ensure access to antiretroviral 
drugs, many lower-income countries are still 
almost entirely dependent on international aid, 
which has declined in recent years. As a result of 
successful therapy and increased life expectancy, 
we are witnessing an increase in the need for 
care for chronic diseases among persons with 
HIV infection. Thus, we need to develop innova-
tive solutions for care delivery, including shift-
ing specific tasks to health workers aside from 
clinicians and integrated service delivery in the 
community.
In conclusion, great progress has been made 
in the global response to the AIDS epidemic, but 
these achievements are fragile because of the 
enormous challenge of sustaining political, pro-
grammatic, and technical commitment, along 
with national and international funding. A cer-
tain level of AIDS fatigue on the part of funders 
and public health and political leaders coincides 
with the unprecedented opportunities for using 
new tools to control AIDS. Prevention and care 
now need to be targeted strategically, and cre-
ative combinations of behavioral, biomedical, 
and structural interventions need to be widely 
implemented.59,60 These programs will require 
universal access, large-scale implementation, 
careful monitoring and evaluation, financial and 
technical resources, and robust commitment. 
Only then may we begin to see a substantial ef-
fect on the global spread of HIV infection.
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